

To: [redacted] [redacted] [redacted] @rivm.nl]
From: [redacted] [redacted]
Sent: Tue 1/21/2020 7:55:13 AM
Subject: RE: please provide input to lab readiness questionnaire 2019-nCoV
Received: Tue 1/21/2020 7:55:25 AM
[Wuhan.pdf](#)

Agree – games ...

I have at 9:00 a call scheduled with [redacted] and if needed will get [redacted] to bring this up again. I already dropped a line that we need to coordinate and that surveys are mushrooming. Just reading the Chinese paper published(in case attached) to catch up...

More soon ☺

[redacted]

From: [redacted] [redacted] <[redacted]@rivm.nl>
Sent: 21 January 2020 08:47
To: [redacted] [redacted] <[redacted]@ecdc.europa.eu>
Subject: RE: please provide input to lab readiness questionnaire 2019-nCoV

Please let us move fast with our questionnaire.....

Second: why is she only referring to you with respect to the Prepare question? (grrrrr)

From: [redacted] [redacted] <[redacted]@ecdc.europa.eu>
Sent: maandag 20 januari 2020 21:35
To: [redacted] [redacted] <[redacted]@erasmusmc.nl>
Cc: [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] <[redacted]@univ-amu.fr>; [redacted] [redacted] <[redacted]@gmail.com>; [redacted] [redacted] <[redacted]@charite.de>
Subject: RE: please provide input to lab readiness questionnaire 2019-nCoV

Then I first do not see too much risk for overlap.

We are rather testing the expert / confirmation level capacity within the countries.

But what do the others think ?

The key will anyhow to exchange all the information between us for action.

Not sure you have heard but we now have the first nosocomial transmissions in Guangdong (not sure it is public yet).

We better have a good night sleep – as we sure will be busy for some time ..

Cheers

[redacted]

From: [redacted] [redacted] <[redacted]@erasmusmc.nl>
Sent: 20 January 2020 21:28
To: [redacted] [redacted] <[redacted]@ecdc.europa.eu>
Cc: [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] <[redacted]@univ-amu.fr>; [redacted] [redacted] <[redacted]@gmail.com>; [redacted] [redacted] <[redacted]@charite.de>
Subject: Re: please provide input to lab readiness questionnaire 2019-nCoV

Thanks for getting back: the exact plan is still in discussion. The coordinator is exploring if PREPARE should be scaled up to do clinical trials. PREPARE has a network of HOSPITAL labs, and mostly from AMR work and trials, so I doubt there will be significant overlap. In a previous round we got very limited response, which of course is a bottleneck if PREPARE would want to scale up fast. Discussion currently is whether to restrict this to labs serving sites that do trials or sending it to all labs (800 or so)

Not sure if it would be published, presumably only as part of a site establishment report or something like that.

5.1.2e

On 20 Jan 2020, at 21:22, [REDACTED] [REDACTED] <[REDACTED]@ecdc.europa.eu> wrote:

Dear [REDACTED]

Thanks for the comments. I agree especially to add the 2 questions re whom to test and who does the triaging.

I think there is no problem in re-cycling the questions per se. When do you want to do the survey within PREPARE ? To whom will it be send ? Will the results be made public or only used with the network ? My only concern is to avoid duplication. As we learnt WHO already went out with some survey, and we should try at least to coordinate a bit in the EU. Not always easy I know.

Many greetings

[REDACTED]

<image373f17.PNG>

<image3081de.GIF>

[REDACTED] [REDACTED] [REDACTED]
 [REDACTED]
 [REDACTED]
 [REDACTED]
 Phone +46 [REDACTED] [REDACTED]
 [REDACTED] [REDACTED]@ecdc.europa.eu

**European Centre for
Disease Prevention and Control (ECDC)**

Gustav III:s boulevard 40, 169 73 Solna, Sweden
 Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01
www.ecdc.europa.eu

Follow ECDC on:

[-image11111.PNG](#) [-image11111.PNG](#) [-image11111.PNG](#) [-image11111.PNG](#)

From: 5.1.2e, 5.1.2e <5.1.2e@erasmusmc.nl>
Sent: 20 January 2020 21:04
To: 5.1.2e, 5.1.2e <5.1.2e@rivm.nl>
Cc: 5.1.2e, 5.1.2e <5.1.2e@univ-amu.fr>; 5.1.2e, 5.1.2e <5.1.2e@gmail.com>; 5.1.2e, 5.1.2e <5.1.2e@charite.de>; 5.1.2e, 5.1.2e <5.1.2e@ecdc.europa.eu>
Subject: Re: please provide input to lab readiness questionnaire 2019-nCoV

Hi

See suggestions, 5.1.2e

Question for 5.1.2e

We are discussing the possibility of a rapid inventory in PREPARE lab net as that needs to understand what capacity the labs serving clinical sites have.

My assessment is that this questionnaire has questions relevant for that, but is probably too long as those labs are mostly microbiology focussed.

Would it be possible to recycle part of this questionnaire for that?

5.1.2e

On 20 Jan 2020, at 16:04, 5.1.2e, 5.1.2e <5.1.2e@rivm.nl> wrote:

Dear all,

1. As announced last Friday, ECDC asked for a quick scan of capacity building for 2019-nCoV in Europe (similar to what we did in 2016 for ZIKV). Please find attached the draft questionnaire for comments.

The questionnaire will be send out to EVD-LabNet members and through ECDC to influenza focal points as in some countries coronaviruses are not diagnosed in the labs that are part of EVD-LabNet but e.g. are NIC.

Especially, the question about the level of validation might improve from your input. See my remark in the text.

Please be so kind to respond by Wednesday. The questionnaire will be send out on Monday as I need some time to build it on-line and as we know times are busy.

2. ECDC has expressed interest in a proficiency assessment for molecular testing for 2019-nCoV within EVD-LabNet. We are currently exploring the most efficient way to do so by joining forces with WHO and EVAg to set-up a joined EQA. More information will follow.

Please let me now if you have any questions and be so kind to provide your comments by Wednesday. I'll keep you posted on any developments with regard to the points above.

Cheers 5.1.2e

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*

<2019-nCoV questionnaire vs 0.3.docx>

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*